Zobrazeno 1 - 3
of 3
pro vyhledávání: '"S. S. Ereshchenko"'
Autor:
D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, A. P. Sokolenko, L. F. Shaykhelislamova, T. T. Tabagua, L. P. Gigolaeva, A. V. Komyakhov, K. S. Nikolaev, K. Yu. Zernov, S. S. Ereshchenko, R. M. Paltuev, A. A. Bessonov, A. S. Artemyeva, R. S. Pesotskiy, N. S. Amirov, A. S. Emelyanov, V. V. Mortada, Ya. I. Bondarchuk, V. V. Semiglazov, T. Yu. Semiglazova, V. F. Semiglazov, A. M. Belyaev
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 1, Pp 48-55 (2023)
Background. BRCA-associated triple negative breast cancer (TNBC) is considered one of the most aggressive subtypes of breast cancer with high sensitivity to chemotherapy, which leads to increased interest in finding new treatment options for patients
Externí odkaz:
https://doaj.org/article/f7969acdde894223bd4331d72b66866d
Autor:
P. V. Krivorotko, V. V. Mortada, R. S. Pesotskiy, A. S. Artemyeva, A. S. Emelyanov, S. S. Ereshchenko, G. A. Dashyan, N. S. Amirov, T. T. Tabagua, L. P. Gigolaeva, A. V. Komyakhov, K. S. Nikolaev, M. M. Mortada, K. Yu. Zernov, E. K. Zhiltsova, V. O. Smirnova, Ya. I. Bondarchuk, D. A. Enaldieva, S. N. Novikov, E. A. Busko, A. V. Chernaya, P. I. Krzhivitskiy, R. M. Paltuev, T. Yu. Semiglazova, V. F. Semiglazov, A. M. Belyaev
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 3, Pp 29-39 (2022)
Background. Achieving a pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) is a predictive factor for improving disease free and overall survival. In triple negative (TN) and HER2-positive breast cancer (BC), the pCR rate exc
Externí odkaz:
https://doaj.org/article/1dba194b85a7496f8bacea07c8744896
Autor:
G. A. Dashyan, V. F. Semiglazov, P. V. Krivorot’ko, T. Yu. Semiglazova, E. E. Topuzov, R. M. Paltuev, K. Yu. Zernov, V. S. Apollonova, S. S. Ereshchenko, A. V. Petrova, E. K. Zhil’tsova, O. A. Ivanova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 12, Iss 1, Pp 46-51 (2016)
Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the
Externí odkaz:
https://doaj.org/article/df195e60b5004d29b0a2524764f3d9a8